Micro Imaging Technology adds staph bacteria to catalog of identifiers
"This is a tremendous step forward for both our technology and our Company," MIT President and CEO Jeff Nunez, said. "We have not only added another Identifier to our catalog, but this opens the door for the MIT 1000 Technology to enter the clinical pathogen detection and identification arena. The Identifier is available now and will soon undergo AOAC certification."
The MIT 1000 is a bacterial cell-based detection and identification system that rapidly identifies pathogenic bacteria in an average of three minutes at half the cost of the industry average.
In October, MIT announced its collaboration with Northern Michigan University's Department of Biology to study and identify Staphylovovvus aureus and Methicillin Resistant strain of S. aureus.
Staph infections can cause a range of health issues, from mild skin problems to fatal conditions if the bacteria reach internal organs. While most infections can be treated easily, some strains of the bacteria are drug-resistant.
"Being able to quickly identify if a patient has an S. aureus infection, and whether or not that S. aureus is MRSA, a strain of S. aureus resistant to certain antibiotics, would be extremely useful in dictating the proper course of treatment for that patient, and ultimately, increase the likelihood of a successful patient outcome," Josh Sharp, NMU biology professor and director of NMU clinical applications of the MIT 1000, said.